CYTOMX THERAPEUTICS INC (CTMX) — insider trading
Health Care · NASDAQ
CYTOMX THERAPEUTICS INC (CTMX) has 12 reported SEC Form 4 insider transactions in our data, including 5 open-market sales among the most recent 12 (latest 2026-06-17).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | Jones Elaine V | Director | Grant / award / vesting (derivative) | 59,000 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Ashworth Alan | Director | Grant / award / vesting (derivative) | 59,000 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Gilbert Halley E | Director | Grant / award / vesting (derivative) | 59,000 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Meyers James R | Director | Grant / award / vesting (derivative) | 59,000 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Mohindru Mani | Director | Grant / award / vesting (derivative) | 59,000 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Young Matthew P. | Director | Grant / award / vesting (derivative) | 59,000 | $0.00 | $0 | Form 4 |
| 2026-06-17 | Su Zhen | Director | Grant / award / vesting (derivative) | 59,000 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Ogden Christopher | Officer (Chief Financial Officer) | Open-market sale | 1,624 | $3.05 | $5.0K | Form 4 |
| 2026-03-17 | Ogden Christopher | Officer (Chief Financial Officer) | Open-market sale | 19,323 | $6.42 | $124.1K | Form 4 |
| 2026-03-17 | BELVIN MARCIA | Officer (SVP, Chief Scientific Officer) | Open-market sale | 31,492 | $6.42 | $202.3K | Form 4 |
| 2026-03-17 | McCarthy Sean A. | Director, Officer (CEO) | Open-market sale | 118,969 | $6.42 | $764.1K | Form 4 |
| 2026-03-17 | Chu Yu-Waye | Officer (Chief Medical Officer) | Open-market sale | 21,279 | $6.42 | $136.7K | Form 4 |
Ask the chat about CTMX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CYTOMX THERAPEUTICS INC (CTMX).
Last updated 2026-06-17 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.